Placebo Controlled Double Blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200, or 300 mg OD, With Amiodarone as Calibrator for the Maintenance of Sinus Rhythm in Patients With Recent Atrial Fibrillation/Flutter.

Trial Profile

Placebo Controlled Double Blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200, or 300 mg OD, With Amiodarone as Calibrator for the Maintenance of Sinus Rhythm in Patients With Recent Atrial Fibrillation/Flutter.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 02 Nov 2012

At a glance

  • Drugs Celivarone (Primary) ; Amiodarone
  • Indications Atrial fibrillation; Atrial flutter
  • Focus Registrational; Therapeutic Use
  • Acronyms MAIA
  • Most Recent Events

    • 07 Jul 2009 Additional location identified as reported by ClinicalTrials.gov.
    • 22 Dec 2008 Planned number of patients changed from 660 to 673 as reported by ClinicalTrials.gov.
    • 22 Dec 2008 Actual end date (May 2006) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top